Autologous renal cell cancer vaccines using heat shock protein-peptide complexes

被引:17
作者
Aalamian, Maryam
Fuchs, Ephraim
Gupta, Renu
Levey, Daniel L. [1 ]
机构
[1] Antigen Inc, Lexington, MA 02421 USA
[2] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA
关键词
heat shock protein; autologous; renal cell carcinoma;
D O I
10.1016/j.urolonc.2005.08.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Investigations into the role of heat shock proteins (HSPs) in immune response have progressed well into a third decade, and indications of their use for the treatment of renal cell carcinoma (RCC) in the adjuvant setting will be revealed in the near future when a randomized phase III clinical trial is completed. Additional ongoing and planned randomized clinical trials will test the efficacy of HSP-based vaccines in more advanced stages of RCC. This review describes the compelling scientific rationale behind testing HSPs in RCC against the backdrop of other immunotherapeutic approaches in this indication. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:425 / 433
页数:9
相关论文
共 98 条
[51]   Peripheral blood mononuclear cell proliferation to heat shock protein-70 derived from autologous lung carcinoma [J].
Michils, A ;
Dutry, D ;
de Beyl, VZ ;
Remmelink, M ;
de Maertelaer, V ;
Rocmans, P .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (05) :749-753
[52]   Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial [J].
Mickisch, GHJ ;
Garin, A ;
van Poppel, H ;
de Prijck, L ;
Sylvester, R .
LANCET, 2001, 358 (9286) :966-970
[53]   Renal-cell carcinoma [J].
Motzer, RJ ;
Bander, NH ;
Nanus, DM .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (12) :865-875
[54]   Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma [J].
Motzer, RJ ;
Murphy, BA ;
Bacik, J ;
Schwartz, LH ;
Nanus, DM ;
Mariani, T ;
Loehrer, P ;
Wilding, G ;
Fairclough, DL ;
Cella, D ;
Mazumdar, M .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2972-2980
[55]   Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up [J].
Nakagawa, T ;
Kami, M ;
Hori, A ;
Kim, SW ;
Murashige, N ;
Hamaki, T ;
Kishi, Y ;
Fujimoto, H ;
Matsuoka, N ;
Kajima, E ;
Komiyama, M ;
Tobisu, K ;
Wakayama, T ;
Uike, N ;
Tajima, K ;
Makimoto, A ;
Mori, S ;
Tanosaki, R ;
Takaue, Y ;
Kakizoe, T .
EXPERIMENTAL HEMATOLOGY, 2004, 32 (07) :599-606
[56]   Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma [J].
Negrier, S ;
Escudier, B ;
Lasset, C ;
Douillard, JY ;
Savary, J ;
Chevreau, C ;
Ravaud, A ;
Mercatello, A ;
Peny, J ;
Mousseau, M ;
Philip, T ;
Tursz, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (18) :1272-1278
[57]   Biochemical, cell biological and immunological issues surrounding the endoplasmic reticulum chaperone GRP94/gp96 [J].
Nicchitta, CV .
CURRENT OPINION IN IMMUNOLOGY, 1998, 10 (01) :103-109
[58]   Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells [J].
Noessner, E ;
Gastpar, R ;
Milani, V ;
Brandl, A ;
Hutzler, PJS ;
Kuppner, MC ;
Roos, M ;
Kremmer, E ;
Asea, A ;
Calderwood, SK ;
Issels, RD .
JOURNAL OF IMMUNOLOGY, 2002, 169 (10) :5424-5432
[59]   GENERATION AND DECAY OF THE IMMUNE-RESPONSE TO A PROGRESSIVE FIBRO-SARCOMA .1. LY-1+2- SUPPRESSOR T-CELLS DOWN-REGULATE THE GENERATION OF LY-1-2+ EFFECTOR T-CELLS [J].
NORTH, RJ ;
BURSUKER, I .
JOURNAL OF EXPERIMENTAL MEDICINE, 1984, 159 (05) :1295-1311
[60]   Interleukin-2, interferon-α and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma:: The all Ireland experience [J].
O'Brien, MF ;
Rea, D ;
Rogers, E ;
Bredin, H ;
Butler, M ;
Grainger, R ;
McDermott, TED ;
Mullins, G ;
O'Brien, A ;
Twomey, A ;
Thornhill, J .
EUROPEAN UROLOGY, 2004, 45 (05) :613-619